Healthcare provider profile · identity verified

Jason Sing, DO

Family Practice · YARDLEY, PA · NPI 1962031559

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	165	70
Amlodipine Besylate	Amlodipine Besylate	111	53
Gabapentin	Gabapentin	106	32
Omeprazole	Omeprazole	79	27
Levothyroxine Sodium	Levothyroxine Sodium	76	32
Hydrochlorothiazide	Hydrochlorothiazide	72	27
Rosuvastatin Calcium	Rosuvastatin Calcium	69	33
Fluticasone Propionate	Fluticasone Propionate	66	27
Albuterol Sulfate Hfa	Albuterol Sulfate	65	23
Alprazolam	Alprazolam	62	11
Lisinopril	Lisinopril	61	27
Trazodone Hcl	Trazodone Hcl	59	17
Carvedilol	Carvedilol	54	16
Escitalopram Oxalate	Escitalopram Oxalate	54	12
Famotidine	Famotidine	54	17
Losartan Potassium	Losartan Potassium	51	26
Metformin Hcl	Metformin Hcl	47	21
Pantoprazole Sodium	Pantoprazole Sodium	47	16
Ezetimibe	Ezetimibe	45	16
Metoprolol Succinate	Metoprolol Succinate	43	13
Valsartan	Valsartan	40	13
Zolpidem Tartrate	Zolpidem Tartrate	40	suppressed
Jardiance	Empagliflozin	39	16
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	39	suppressed
Simvastatin	Simvastatin	35	14
Bupropion Xl	Bupropion Hcl	32	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Montelukast Sodium	Montelukast Sodium	31	11
Quetiapine Fumarate	Quetiapine Fumarate	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Ibuprofen	Ibuprofen	29	12
Ozempic	Semaglutide	28	12
Lamotrigine	Lamotrigine	26	suppressed
Clonazepam	Clonazepam	25	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	25	suppressed
Clopidogrel	Clopidogrel Bisulfate	24	11
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Rybelsus	Semaglutide	22	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Phenobarbital	Phenobarbital	21	suppressed
Memantine Hcl	Memantine Hcl	20	suppressed
Metformin Hcl Er	Metformin Hcl	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Glipizide Er	Glipizide	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	11
Tamsulosin Hcl	Tamsulosin Hcl	19	suppressed
Allopurinol	Allopurinol	18	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	18	suppressed
Mounjaro	Tirzepatide	18	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	18	suppressed
Eliquis	Apixaban	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Meloxicam	Meloxicam	17	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Celecoxib	Celecoxib	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Vraylar	Cariprazine Hcl	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Tramadol Hcl	Tramadol Hcl	15	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Vilazodone Hcl	Vilazodone Hcl	13	suppressed
Baclofen	Baclofen	12	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Sertraline Hcl	Sertraline Hcl	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Furosemide	Furosemide	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Lubiprostone	Lubiprostone	11	suppressed
Prempro	Estrogen,con/M-Progest Acet	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error